Innovations in CAR T cell therapies are improving efficacy against solid tumors. Australian researchers used CRISPR to engineer CAR T cells with additional cancer-fighting protein activation at tumor sites, enhancing target specificity. Separately, San Raffaele-Telethon Institute demonstrated that engineered cellular communication boosts CAR T effectiveness against glioblastoma, addressing this aggressive brain cancer’s treatment resistance. These advances promise to expand CAR T applicability beyond hematologic malignancies.